Published content in this website is for information purposes and is intended for healthcare professionals only.
Glossary of key terms in PSP
Grasping PSP's intricacies hinges on understanding key definitions and concepts. Familiarity with these principles will help you navigate its complexities.
Familial PSP
Cases of PSP that occur in multiple members of the same family, suggesting a hereditary component.
FNP-223
Investigational, brain-penetrant, selective OGA inhibitor intended as a potential DMT for PSP.
Frontal cognitive/behavioral presentation
Defined as at least three of the following features, which have to be persistent: apathy; bradyphenia; dysexecutive syndrome; reduced phonemic verbal fluency; impulsivity, disinhibition, or perseveration.
Frontal dysfunction
Impairment of the frontal lobe, which affects executive, cognitive, or behavioral functions.
Referencias
-
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853-864. doi:10.1002/mds.26987
-
Donker Kaat L, Boon AJ, Azmani A, et al. Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology. 2009;73(2):98-105. doi:10.1212/WNL.0b013e3181a92bcc
-
Permanne B, Sand A, Ousson S, et al. O-GlcNAcase inhibitor ASN90 is a multimodal drug candidate for tau and α-synuclein proteinopathies. ACS Chem Neurosci. 2022;13(8):1296-1314. doi:10.1021/acschemneuro.2c00057
-
Pirau L, Lui F. Frontal lobe syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Nov]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532981/